The business model for antibiotics is broken - High volume sales of antibiotics drive evolutionary resistance. So why do we allow most of the supply chain to make money based on the volume of sales? This wasteful practice might be tolerated if antibiotic innovation was easy and plentiful. But in the world we live in, alternative business models are needed for antibiotics. See  http://ow.ly/2Fwuwk
Add a comment...